Physician profile
Steven Rich
NPI 1902118714
$1,013.74
in general payments reported to CMS, 2019-2025
15 companies · $165 in 2025
The $165 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.90 · 2020: $104 · 2021: $124 · 2022: $209 · 2023: $166 · 2024: $233 · 2025: $165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $564.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $564.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $253.21 | 2020-2024 | Jornay Pm |
| Corium, LLC | $134.14 | 2022-2025 | Azstarys, Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $127.32 | 2020-2021 | |
| Cranial Technologies, INC | $97.05 | 2021-2025 | Doc Band |
| Glaxosmithkline, LLC. | $93.15 | 2019-2025 | Bexsero |
| Merck Sharp & Dohme LLC | $78.92 | 2022-2024 | Gardasil 9, Vaxneuvance, Rotateq |
| Tris Pharma INC | $40.46 | 2025 | Quillivant, Onyda Xr |
| Supernus Pharmaceuticals, INC. | $36.22 | 2022-2023 | Qelbree |
| Collegium Pharmaceutical, INC. | $34.20 | 2025 | Jornay Pm |
| Pfizer INC. | $34.00 | 2021-2022 | |
| Biomerieux INC | $30.66 | 2024 | Biofire Spotfire Respiratory (R) Panel |
| Sobi, INC | $14.67 | 2023 | |
| Verrica Pharmaceuticals INC. | $14.59 | 2024 | Ycanth |
| Astrazeneca Pharmaceuticals LP | $12.66 | 2021 | |
| Sanofi Pasteur INC. | $12.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Rich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.